Stada plots path forward with Goldschmidt at helm
This article is powered by OTC Bulletin & The Rose Sheet
“Continuing to market a competitive portfolio” and “working closely with our global network of strategic development and production partners” are among the long-term priorities of Stada Arzneimittel’s newly-appointed chief executive officer Peter Goldschmidt.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.